HVC
Healthcare Value Capital Portfolio holdings
AUM
$38.5M
This Quarter Return
+2.74%
1 Year Return
+22.29%
3 Year Return
+31.09%
5 Year Return
+125.72%
10 Year Return
–
AUM
$28.5M
AUM Growth
+$28.5M
(-32%)
Cap. Flow
-$12.1M
Cap. Flow
% of AUM
-42.61%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
12
New
1
Increased
2
Reduced
–
Closed
2
Top Buys
| 1 |
NVLN
Novelion Therapeutics Inc. Common Shares
NVLN
|
$370K |
| 2 |
Standard BioTools
LAB
|
$295K |
| 3 |
SEEL
Seelos Therapeutics, Inc. Common Stock
SEEL
|
$184K |
Top Sells
| 1 |
Pfizer
PFE
|
$8.93M |
| 2 |
Assertio
ASRT
|
$4.05M |
Sector Composition
| 1 | Healthcare | 98.06% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
TYME
1
DELISTED
Tyme Technologies, Inc. Common Stock
TYME
| $13.2M | 40.26% | 2,075,000 | – | – |
|
2
Gilead Sciences
GILD
$140B
| $5.37M | 16.34% | 75,000 | – | – |
|
|
NVLN
3
DELISTED
Novelion Therapeutics Inc. Common Shares
NVLN
| $3.12M | 9.49% | 1,000,000 +118,560 | +13% | +$370K |
|
|
4
Standard BioTools
LAB
$481M
| $2.42M | 7.35% | 410,500 +50,000 | +14% | +$295K |
|
|
AMRN
5
Amarin Corp
AMRN
$311M
| $1.81M | 5.49% | 450,000 | – | – |
|
6
GSK
GSK
$79.9B
| $1.77M | 5.39% | 50,000 | – | – |
|
7
ProShares UltraShort NASDAQ Biotechnology
BIS
$2.47M
| $551K | 1.68% | 25,000 | – | – |
|
|
SEEL
8
DELISTED
Seelos Therapeutics, Inc. Common Stock
SEEL
| $184K | 0.56% | +100,000 | New | +$184K |
|
|
9
Assertio
ASRT
$80.4M
| – | – | -700,000 | Closed | -$4.05M |
|
10
MannKind Corp
MNKD
$1.41B
| – | – | 0 | – | – |
|
|
11
Pfizer
PFE
$141B
| – | – | -250,000 | Closed | -$8.93M |
|
|
FCSC
12
DELISTED
Fibrocell Science Inc.
FCSC
| – | – | 0 | – | – |
|